Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE).
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2014
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESPONSE
- Sponsors Genentech
- 03 Aug 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 03 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2009 New trial record.